Akari Therapeutics Valuation
| AKTX Stock | USD 0.91 0.06 6.19% |
Today, the firm appears to be undervalued. Akari Therapeutics PLC shows a prevailing Real Value of $14.48 per share. The current price of the firm is $0.91000003. Our model approximates the value of Akari Therapeutics PLC from analyzing the firm fundamentals such as current valuation of 25.23 M, and Return On Equity of -12.81 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Akari Therapeutics' valuation include:
Undervalued
Today
Please note that Akari Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Akari Therapeutics PLC is based on 3 months time horizon. Increasing Akari Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Akari Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Akari Stock. However, Akari Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.91 | Real 14.48 | Target 55.0 | Hype 1.0 | Naive 1.1 |
The intrinsic value of Akari Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Akari Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Akari Therapeutics PLC helps investors to forecast how Akari stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Akari Therapeutics more accurately as focusing exclusively on Akari Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Akari Therapeutics' intrinsic value based on its ongoing forecasts of Akari Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Akari Therapeutics' closest peers.
Akari Therapeutics Cash |
|
Akari Valuation Trend
Analysing the historical paterns of Akari Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Akari Therapeutics PLC over time and is usually enough for investors to make rational market timing decisions.
Akari Therapeutics Total Value Analysis
Akari Therapeutics PLC is presently anticipated to have valuation of 25.23 M with market capitalization of 30.35 M, debt of 4.58 M, and cash on hands of 8.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Akari Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
25.23 M | 30.35 M | 4.58 M | 8.15 M |
Akari Therapeutics Asset Utilization
One of the ways to look at asset utilization of Akari is to check how much profit was generated for every dollar of assets it reports. Akari Therapeutics PLC shows a negative utilization of assets of -1.73 percent, losing $0.0173 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Akari Therapeutics PLC shows how unproductive it operates for each dollar spent on its assets.Akari Therapeutics Ownership Allocation
Akari Therapeutics holds a total of 20.65 Million outstanding shares. Akari Therapeutics PLC shows 11.9 percent of its outstanding shares held by insiders and 0.5 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Akari Therapeutics Profitability Analysis
Net Loss for the year was (10.01 M) with profit before overhead, payroll, taxes, and interest of 0.About Akari Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Akari Therapeutics. We calculate exposure to Akari Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Akari Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.6 K | -4.8 K |
Akari Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 4.9 M |
Akari Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Akari Therapeutics PLC and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Akari we look at many different elements of the entity such as Akari's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Akari Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Akari Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Akari Therapeutics' worth.Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.